Instylla develops next-generation liquid embolics for peripheral vascular embolotherapy and interventional oncology, with its first product Embrace HES designed for controlled, complete, and persistent embolization. The company is led by CEO Amar Sawhney and was founded in 2017 by Incept LLC. Instylla’s HES Hypervascular Tumor Pivotal Study is enrolling patients in the US and Canada to evaluate the Hydrogel Embolic System versus standard of care, and the HALT Study is enrolling to study Embrace HES for embolization of arterial bleeding. The company intends to use the proceeds from the recent financing to support ongoing prospective clinical trials and early commercialization. Instylla is based in Bedford, MA. Instylla develops the Hydrogel Embolic System (HES™), a water‑based liquid injected via standard catheters that fills target vessels and solidifies into a soft, occlusive, absorbable hydrogel causing immediate and persistent flow stasis. The company is led by CEO Amar Sawhney and was founded by Incept LLC in 2017. Instylla recently closed a $25.4M Series B financing to fund its clinical and regulatory plans. Management intends to use the proceeds to conduct several prospective clinical trials, including a pivotal trial in the United States, in preparation for market entry. The HES is not approved for sale in the United States. The financing also includes board additions as part of the round.

Total raised

$55M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2023